1/17/2024 0 Comments Regeneron checkmate![]() ![]() Prior to that, Veronica was Global Product Leader for the cancer therapies Calquence and Lumoxiti at AstraZeneca and led Medical Affairs for the Hematology Franchise at Roche where she was also involved in the development of a range of oncology programs. Veronica joined Autolus from TargImmune Therapeutics AG, where she was Chief Medical Officer. ![]() Veronica Hersberger was appointed as Senior Vice President, Medical Affairs in Q2 2023 and has started to build up this critical function as the Company prepares obe-cel for launch. Lucinda Crabtree, who, as previously announced, will be leaving Autolus in August. He brings more than 20 years of diversified experience as a life sciences financial executive driving the strategy, planning, execution, and financing of private and public biopharmaceutical companies. Dolski joins Autolus from Checkmate Pharmaceuticals Inc., where he served as Chief Financial Officer at the clinical-stage immuno-oncology biotech, acquired by Regeneron Pharmaceuticals Inc. Dolski as Chief Financial Officer (CFO), effective August 7, 2023. LONDON, J(GLOBE NEWSWIRE) - Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced the appointment of Robert F. Miranda Neville promoted to Senior Vice President, Project Management and will continue to lead the obe-cel program Veronica Hersberger appointed as Senior Vice President, Medical Affairs Autolus Therapeutics announces appointment of Robert F. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |